Gamble Program for Clinical Studies

Research Emphasis

Areas of research emphasis include:

Herpes viral diseases (gential herpes, cold sores, congenital CVM)
Respiratory diseases (influenza, respiratory syncytial virus, common cold, pneumococcal pneumonia)
Diarrheal diseases (rotavirus, norovirus, bacterial)
Microbicides
Sexually transmitted diseases (HPV)
Infections in international adoptees

Vaccine research has included clinical evaluations in all age groups (infants to elderly). Specific vaccines include:

Influenza
Cytomegalovirus (CMV) (inactivated and live-attenuated)
Herpes type 1 and 2 (HSV)
Rotavirus
Acellular pertussis
Meningicoccal
Pneumococcal
Respiratory syncytial virus (RSV)
Parainfluenza
Parvovirus
Cholera
Norovirus
Salmonella
Human papillomavirus (HPV)
New combinations of childhood vaccines

Highlights: The highlight of the Gamble Program was the licensure of the rotavirus vaccine developed by Gamble investigators Richard Ward and David Bernstein. The vaccine licensed to GlaxoSmithKline and sold as Rotarix™ is available in over 100 countries including the United States and Europe.

Antiviral drug research has included evaluation of agents for:

Influenza
Rhinovirus
Genital Herpes
Herpes labialis
Enteroviruses

These studies have involved natural and experimental viral challenges.

Over the years, the Gamble Program has been well funded. Current funding includes an NIH VTEU (vaccine treatment and evaluation unit) contract, an NIH antiviral contract, and numerous industrial sponsors.